Due to confidentiality agreements, the identities of the trial individuals remain undisclosed. Eli Lilly, the pharmaceutical business guiding retatrutide, declined to touch upon the protocols of its ongoing trials but mentioned that individual protection is actually a precedence.Retatrutide—the groundbreaking triple-action peptide revolutionizing